Using advanced imaging to improve treatment for gastric cancer
The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer
This study is testing if special imaging techniques can help doctors better treat and understand how well neoadjuvant therapy works for patients with gastric cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 32 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06327386 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the therapeutic efficacy of 18F-FDG combined with 18F-FAPI PET/MR imaging in patients with primary gastric adenocarcinoma undergoing neoadjuvant therapy. It will involve collecting clinical data, performing imaging assessments, and analyzing pathological specimens to determine the effectiveness of the imaging techniques in staging and treatment response. The study will take place at Daping Hospital from January 2024 to January 2026, focusing on patients who have undergone surgical resection after neoadjuvant treatment. Statistical analyses will be conducted to compare imaging results and clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with primary gastric adenocarcinoma who are eligible for neoadjuvant therapy and surgical resection.
Not a fit: Patients with severe comorbidities, poor imaging quality, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of staging and treatment response assessment in gastric cancer, potentially leading to improved surgical outcomes.
How similar studies have performed: While the use of PET/MR imaging in cancer treatment is gaining traction, this specific combination in the context of gastric cancer neoadjuvant therapy is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed primary gastric adenocarcinoma patients (cT2N+non-surgical treatment, cT3NanyMany and above staging) * Staging of MRI enhanced examination before neoadjuvant therapy * Restaging of preoperative 18F-FAPI and 18F-FDG PET/MRI examination * Postoperative resection was performed after neoadjuvant therapy, with postoperative pathology, regression grading, and related immunohistochemistry * Patient age ≥ 18 years old * The patient voluntarily participates and signs an informed consent form. Exclusion Criteria: * Severe comorbidities may interfere with treatment or affect disease-specific health-related quality of life * Drug requirements that interfere with the research protocol * Pregnant or lactating male subjects who are expected to conceive or cause their spouse to conceive during the planned trial period * The imaging quality is poor and cannot be used for diagnosis and evaluation.
Where this trial is running
Chongqing, Chongqing Municipality
- Department of Nuclear Medicine, Daping Hospital of Army Medical University — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiao Chen, Ph.D
- Email: xiaochen229@foxmail.com
- Phone: +8615922970174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.